| rituximab n: 53 | infliximab n: 6 | Etarnercept n: 35 | adalimumab n: 45 | Total n: 139 |
| ||
| 45.1 ± 12.4 (19 - 72) | 50.4 ± 5.4 (45 - 58) | 46.2 ± 15.8 (19 - 97) | 45.9 ± 12.2 (22 - 72) | 46 ± 13 (19 - 97) | Age ( Years) ± SD Range | ||
| 41 (77.4) | 3 (6) | 32 (91.4) | 42 (91.3) | 118 (84.9) | Females, n % | ||
| 8.4 (2 - 45) 8 (15.1) 45 (84.9) | 11.2 (0.5 - 18) - 5 (100%) | 6.4 (0.8 - 30) 2 (6) 32 (94) | 5.9 (0.8 - 23) 6 (14) 37 (86) | 7.24 (1 - 45) 16 (11.8) 121 (88.2) | Duration Mean (Years) Range (Years) Disease < 1 Year, no % Disease > 1 Year, no % | ||
| 34 (66) | 4 (80) | 22 (62.9) | 28 (60.9) | 88 (63.3) | RF+ ve, n% | ||
| 41 (77.4) | 6 (100) | 25 (71.4) | 37 (84.8) | 110 (78.4) | ACPA+ ve, n % | ||
|
4 |
1 |
1 |
2 |
8 (5.8) | Chest X-Ray Fibrosis (n %) | ||
| 5 | - | 2 | 4 | 11 (8.4) | TB Exposure n (%) | ||
| 9 | - | 3 | 5 | 17 (12.2) | PPD Test > 5 mm, n (%) | ||
| 9 | - | 3 | 5 | 17 (12.2) | INH Prophylaxis n (%) | ||
|
13 (44.8) 15 (36.6) 25 (41) |
1 (3.4) 2 (4.9) 2 (3.3) |
9 (31.0) 11 (26.8) 11 (18) |
6 (20.7) 13 (31.7) 23 (39.2) |
29 (24.) 41 (30.7) 61 (45.3) | Cormorbidity n (%) No Cormorbid Illness 1 Cormorbid Illness ≥2 Cormorbid Illness | ||
|
7 0 |
3 1 |
3 0 |
6 0 |
19 (13.6) 1 | Nodules n (%) Baseline Durning Follow Up | ||
|
13 (24.5) 40 (80.5) 45 (84.9) |
0 6 (100) 6 (100) |
4 (11.4) 27 (77.1) 31 (88.6) |
14 (30.4) 29 (61.0) 34 (73.3) |
31 (22%) 101 (72%) 115 (83%) | DMARDs n (%) 1 DMARD ≥2 DMARDs Metrotrexate | ||
| 53 (38.1) 31 (22.0) 23 (75.9) | 6 (4.3) 22 (15.8) 1 (3.3) | 35 (25.2) 32 (23) 4 (13.2) | 45 (32.2) 44 (31.7) 5 (16.5) | 139 139 33 (45.87) | Present Biologicals n (%) Choice of 1st Biological n (%) Choice of 2nd Biological n (%) | ||